- Home
- CUBI vs AKRO Comparison
CUBI vs AKRO Comparison
Compare CUBI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- AKRO
- Stock Information
- Founded
- CUBI 1994
- AKRO 2017
- Country
- CUBI United States
- AKRO United States
- Employees
- CUBI N/A
- AKRO N/A
- Industry
- CUBI Major Banks
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- CUBI Finance
- AKRO Health Care
- Exchange
- CUBI Nasdaq
- AKRO Nasdaq
- Market Cap
- CUBI 1.4B
- AKRO 2.1B
- IPO Year
- CUBI 2012
- AKRO 2019
- Fundamental
- Price
- CUBI $46.46
- AKRO $31.59
- Analyst Decision
- CUBI Buy
- AKRO Strong Buy
- Analyst Count
- CUBI 8
- AKRO 7
- Target Price
- CUBI $63.86
- AKRO $43.20
- AVG Volume (30 Days)
- CUBI 290.2K
- AKRO 441.5K
- Earning Date
- CUBI 10-31-2024
- AKRO 11-11-2024
- Dividend Yield
- CUBI N/A
- AKRO N/A
- EPS Growth
- CUBI 33.08
- AKRO N/A
- EPS
- CUBI 7.41
- AKRO N/A
- Revenue
- CUBI $722,462,000.00
- AKRO N/A
- Revenue This Year
- CUBI N/A
- AKRO N/A
- Revenue Next Year
- CUBI $11.71
- AKRO N/A
- P/E Ratio
- CUBI $6.12
- AKRO N/A
- Revenue Growth
- CUBI 25.87
- AKRO N/A
- 52 Week Low
- CUBI $38.69
- AKRO $11.36
- 52 Week High
- CUBI $68.49
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- CUBI 48.18
- AKRO 66.34
- Support Level
- CUBI $44.31
- AKRO $29.34
- Resistance Level
- CUBI $47.11
- AKRO $32.15
- Average True Range (ATR)
- CUBI 1.57
- AKRO 1.26
- MACD
- CUBI 0.05
- AKRO 0.10
- Stochastic Oscillator
- CUBI 28.96
- AKRO 99.74
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources, and Financial Products and Services. The majority of revenue is derived from commercial lending.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.